生化学の領域は非常に広く,各専門教育の導入として重要な科目であります。2年生後期には主として一般生化学の内容となる口腔生化学Iを担当し,3年前期には結合組織,カルシウム代謝,唾液成分,齲蝕のメカニズムなどを中心とした口腔生化学IIを担当しています。この他,他科との連携を重視し,多角的に理解を深めるようなカリキュラムを組んでいます。

私たちの教育理念は,生体の代謝を学び,いかに生体恒常性が維持されているか,また,代謝の破綻が病気を引き起こすことや異常代謝を人為的に調節することが病気の治療の基本であることを平易に教授し,高質な歯科医療を行うことのできる人材を育成することであります。私たちは,専門知識の習得のみならず,医療従事者で共通した基礎知識の習得は,チーム医療を支える共通認識につながると考えています。

硬組織に関する研究、特に骨芽細胞の分化制御に関する研究や,がん細胞の生物学的特性、特に癌細胞の転移の機構に関する研究を行っております.
私たちの研究室では,大学院歯学研究科口腔生理生化学専攻科目として,次の研究を行っております.

1. 骨芽細胞分化の制御機構の解析
2. オステオネクチンの生理活性の解析
3. オステオネクチンノックアウトマウスの解析
4. 癌細胞の浸潤転移機構の解析
5. 酸性微小環境と癌細胞の悪性形質に関する研究
6. 酸性細胞外pHに対する細胞内情報伝達機構の解析

上記に興味のある仲間(学部生,大学院生など)を随時募集しております。
共同研究も大歓迎です!
一緒に未知の領域を探索してみませんか?

加藤　靖正

カトウ　ヤスマサ

教授

前田　豊信

マエダ　トヨノブ

教授

• 日本癌学会
• 日本がん転移学会
• 歯科基礎医学会
• 日本生化学会
• 日本骨代謝学会
• 日本結合組織学会
• 日本歯科医学教育学会
• 奥羽大学歯学会
• The Metastasis Research Society
• American Society of Biochemistry and Molecular Biology
• International Society of Cancer Metabolism

業績(2010年～2023年)

(1)和文著書

1. 加藤靖正.第1章 生化学に必要な化学の基礎,第15章 癌の生化学,In: スタンダード生化学・口腔生化学第4版(編集・執筆:荒川俊哉,池尾　隆,加藤靖正,古株彰一郎,近藤信夫,自見英治郎,鈴木直人,半田慶介,坂東健二郎,平塚浩一;執筆:川木晴美,高井理衣,髙田鮎子,髙山英次,田邉奈津子,津田啓方,堂前英資,藤田　厚,吉川美弘; ISBN: 978-4-7624-3633-8), 学研書院, 東京, p.2-11; 318-331, 2023. [Publisher site]
2. 馬場 優, 高田 訓, 加藤靖正.口腔癌におけるEGFR阻害剤の効果予測因子. BIO Clinica 34(9), 39-41, 2019. [Publisher site]
3. 加藤靖正,前田豊信,鈴木厚子.酸性細胞外pH:がん転移に関連する微小環境. 細胞 50(5), 32-36, 2018.[Publisher site]
4. 加藤靖正.第1章 生化学に必要な化学の基礎,第15章 癌の生化学,In: スタンダード生化学・口腔生化学第3版(編集・執筆:池尾 隆,加藤靖正,近藤信夫,自見英治郎,鈴木直人,友村明人,平塚浩一;執筆:大塚吉兵衛,神谷真子,川木晴美,合田征司,髙山英次,友村美根子,坂東健二郎,藤田 厚,前野正夫; ISBN: 78-4-7624-2633-9), 学研書院, 東京, p.2-9 & 310-325, 2012. [Publisher site]
5. 加藤靖正.第2章 がんはどうしてできるか,In: 口腔生化学第6版(監修:早川太郎、須田立雄、木崎治俊; ISBN: 978-4-263-456-45-3),医歯薬出版,東京,p. 301-338, 2011. [Publisher site]

(2)英文著書

1. Baba Y, Nishiyama T, Kato Y. Diagnosis and treatment of accessory parotid gland tumors, In: International manual of oncology practice (Eds: de Mello RA, Tavares A, Mountzios G; ISBN: 978-3-319-21682-9), Springer, Cham, Switzerland, p.123-140, 2012. doi: 10.1007/978-3-319-21683-6 [Publisher site]
2. Baba Y, Fujii M, Tokumaru Y, Kato Y. Overcoming resistance to EGFR inhibitor in head and neck cancer (Chapter 1), In: The research and biology of cancer II (Eds: Shoja MM, Agutter PS, Tubbs RS, Ghanei M, Ghabili K, Harris A, Loukas M; ISBN: 978-14775549-9-9), iConcept Press, Hong Kong, China, p.1-18, 2012.
3. Baba Y, Fujii M, Tokumaru Y, Kato Y. A proposal for a new strategy in head and neck cancer: combination therapy targeting the PI3kinase/Akt and EGFR signaling pathways (Chapter 12), In: Hypothesis in clinical medicine (Eds: Shoja MM, Agutter PS, Tubbs RS, Ghanei M, Ghabili K, Harris A, Loukas M; ISBN: 978-1-62257-285-4), Nova Science Publishers, New York, USA, p.181-198, 2012. [Publisher site]
4. Baba Y, Fujii M, Tokumaru Y, Kato Y. Cell Signalings and the Communications in Head and Neck Cancer, In: Head and Neck Cancer (Ed: Agulnik, M; ISBN: 978-953-51-0236-6), InTech, Rijeka, p.123-140, 2012. [Publisher site]

(3)Peer-reviewed/invited papers

1. Furuya G, Katoh H, Atsumi S, Hashimoto I, Komura D, Hatanaka R, Senga S, Hayashi S, Akita S, Matsumura H, Miura A, Mita H, Nakakido M, Nagatoishi S, Sugiyama A, Suzuki R, Konishi H, Yamamoto A, Abe H, Hiraoka N, Aoki K, Kato Y, Seto Y, Yoshimura C, Miyadera K, Tsumoto K, Ushiku T, Ishikawa S. Nucleic Acid-triggered Tumoral Immunity Propagates pH-selective Therapeutic Antibodies through Tumor-driven Epitope Spreading. Cancer Sci, in press.
2. Kobayashi-Sakamoto M, Maeda T, Kimura M, Yusa J, Ito H, Tani H, Kato Y, Hirose K. Bovine lactoferrin increases the poly(I:C)-induced antiviral response in vivo. Biochem Cell Biol 2022 Aug 18. doi: 10.1139/bcb-2021-0342. Online ahead of print [Pub-Med]
3. Baba Y, Takada S, Kato Y. In reference to risk perception of septic shock with multiple organ failure due to acute exacerbation of an infectious dental disease. Ther Clin Risk Manag 17: 1163-1164, 2021. doi: 10.2147/TCRM.S342486 [Pub-Med]
4. Funakawa T, Kawanabe H Usami A, Takahashi K, Kato Y, Baba Y. The importance of early detection for postoperative maxillary cyst before dental implantation: A case report. Int J Surg Case Rep 86: 106370, 2021. doi: 10.1016/j.ijscr.2021.106370 [Pub-Med]
5. Baba Y, Kato Y. Letter to the Editor: In reference to COVID-19 and the otolaryngologist: preliminary evidence-based review. Laryngoscope 131: E1460, 2021. doi: 10.1002/lary.29412 [Pub-Med]
6. Baba Y, Takada S, Segawa H, Kato Y. Different management between emergent infectious diseases and emergent non-infectious diseases during COVID-19 pandemic in a head and neck unit. Braz J Infect Dis S1413-8670(20), 30106–301069. doi: 10.1016/j.bjid.2020.07.007.[Pub-Med]
7. Kojima T, Maeda T, Suzuki A, Yamamori T, Kato Y. Intracellular zinc-dependent TAS2R8 gene expression through CTCF activation. Biomed Res (Tokyo) 41 (5), 217–225, 2020.
8. Suzuki-Yamazaki M, Takahashi K, Takada S, Kato Y, Baba Y. A successful treatment regimen for the prevention of sinusitis after maxillary sinus floor elevation surgery in a high-risk case. Case Rep Otolaryngol 2020, 6869805, 2020. doi: 10.1155/2020/6869805 [Pub-Med]
9. Baba Y, Takada S, Segawa H, Kato Y. Different management between emergent infectious diseases and emergent non-infectious diseases during COVID-19 pandemic in a head and neck unit. Braz J Infect Dis S1413-8670(20), 30106-30109, 2020. doi: 10.1016/j.bjid.2020.07.007 [Pub-Med]
10. Kobayashi-Sakamoto M, Maeda T, Yusa J, Kato Y, Kiyoura Y. RANK-RANKL signaling upregulates Il-10 mRNA expression in mucosal Candida infection in vivo. Microb Pathog 149, 104285, 2020. doi: 10.1016/j.micpath.2020.104285 [Pub-Med]
11. Baba Y, Kato Y. Letter to the Editor (Confusion of epipen trainer with epipen caused by a pharmacist). J Paediatr Child Health 56(5), 826-827, 2020. doi: 10.1111/jpc.14884 [Pub-Med]
12. Sutoo S, Maeda T, Suzuki A, Kato Y. Adaptation to chronic acidic extracellular pH elicits a sustained increase in lung cancer cell invasion and metastasis. Clin Exp Metastasis 37(1), 133-144, 2020. doi: 10.1007/s10585-019-09990-1[Pub-Med]
13. Nagaoka M, Maeda T, Chatani M, Handa K, Yamakawa T, Kiyohara S, Negishi-Koga T, Kato Y, Takami M, Niida S, Lang SC, Kruger MC, Suzuki K. A Delphinidin-Enriched Maqui Berry Extract Improves Bone Metabolism and Protects against Bone Loss in Osteopenic Mouse Models. Antioxidants (Basel) 8(9), E386, 2019. doi: 10.3390/antiox8090386 [Pub-Med]
14. Nagaoka M, Maeda T, Moriwaki S, Nomura A, Kato Y, Niida S, Kruger MC, Suzuki K.. Petunidin, a B-ring 5'-O-methylated derivative of delphinidin, stimulates osteoblastogenesis and reduces sRANKL-induced bone loss. Int J Mol Sci 20(11), 2795, 2019. doi: 10.3390/ijms20112795 [Pub-Med]
15. 渡部敏恵,衛藤雅昭,小池勇一,佐藤 研,加藤靖正,馬場 優. 4種ウイルス感染症における抗体陽性率および感受性率の年次推移について-麻疹・風疹・ムンプス・水筒の血清抗体価解析-. Campus Health 56(2), 104-110, 2019. doi: 10.18632/oncotarget.20826 [Publisher site]
16. Zijlstra A, Von Lersner A, Yu D, Borrello, B, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox T, Price J, Kato Y, Welm A, Aguirre-Ghiso J. The importance of developing therapies targeting the biological spectrum of metastatic disease. Clin Exp Metastasis 36(4), 305–309, 2019. doi: 10.1007/s10585-019-09972-3 [Pub-Med]
17. Sumida R, Maeda T, Kawahara I, Yusa J, Kato Y. Platelet?rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor?κB ligand ratio in osteoblasts. Exp Ther Med, 2019. doi: https://doi.org/10.3892/etm.2019.7560 [Publisher site]
18. Yang XY, Ozawa S, Kato Y, Maehata Y, Izukuri K, Ikoma T, Kanamori K, Akasaka T, Suzuki K, Iwabuchi H, Kurata SI, Katoh I, Sakurai T, Kiyono T, Hata RI. C-X-C Motif Chemokine Ligand 14 is a Unique Multifunctional Regulator of Tumor Progression. Int J Mol Sci 20(8), E1872, 2019. doi: 10.3390/ijms20081872 [Pub-Med]
19. Kato Y, Maeda T, Suzuki A, Baba Y. Cancer metabolism: New insights into classic characteristics. Jpn Dent Sci Rev 54(1), 8-21, 2018. doi: 10.1016/j.jdsr.2017.08.003 [Pub-Med]
20. Baba Y, Kato Y. Deguelin, a novel anti-tumorigenic agent in human esophageal squamous cell carcinoma. EBioMedicine 26(10), 10, 2017. doi: 10. doi: 10.1016/j.ebiom.2017.11.010 [Pub-Med]
21. Fingleton B, Lange K, Caldwell B, Bankaitis KV; Board of the Metastasis Research Society (Kang Y, Yu D, Aguirre-Ghiso J, Cox TR, Erler JT, Gelman IH, Hurst DR, Kato Y, Lynch CC, Price JT, Samant RS, Sleeman J, Stein U, Zijlstra A). Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example. Clin Exp Metastasis 34(8), 443-447, 2017. doi: 10.1007/s10585-017-9872-8 [Pub-Med]
22. Maeda T, Suzuki A, Koga K, Miyamoto C, Maehata Y, Ozawa S, Hata RI, Nagashima Y, Nabeshima K, Miyazaki K, Kato Y. TRPM5 mediates acidic extracellular pH signaling and TRPM5 inhibition reduces spontaneous metastasis in mouse B16-BL6 melanoma cells. Oncotarget 8(45), 78312-78326, 2017. doi: 10.18632/oncotarget.20826 [Pub-Med]
23. Baba Y, Kato Y. Promising biomarkers to predict the efficacy of inhibitors of the epidermal growth factor receptor tyrosine kinase in head and neck squamous cell carcinoma. Biomarkers J 3:6, 2017. doi: 10.21767/2472-1646.100028 [Publisher site]
24. Baba Y, Maeda T, Suzuki A, Takada S, Fujii M, Kato Y. Deguelin Potentiates Apoptotic activity of an EGFR tyrosine kinase inhibitor (AG1478) in PIK3CA-mutated head and neck squamous cell carcinoma. Int J Mol Sci 18(2), E262, 2017. doi: 10.3390/ijms18020262 [Pub-Med]
25. Maeda T, Yuzawa S, Suzuki A, Baba Y, Nishimura Y, Kato Y. RhoA mediates the expression of acidic extracellular pH-induced matrix metalloproteinase-9 mRNA through phospholipase D1 in mouse metastatic B16-BL6 melanoma cells. Int J Oncol 48(3), 1251-1257, 2016. doi: 10.3892/ijo.2016.3322 [Pub-Med]
26. Baba Y, Kato Y. The role of bevacizumab in the management of head and neck squamous cell carcinoma patients. Chemotherapy 4(3); 1000163, 2015. doi: 10.4172/2167-7700.1000163 [Publisher site]
27. Maeda T, Suzuki A, Yuzawa S, Baba Y, Kimura Y, Kato Y. Mineral trioxide aggregate induces osteoblastogenesis via Atf6. Bone Rep 2, 36-43, 2015. doi:10.1016/j.bonr.2015.03.003 [Pub-Med]
28. Nishiyama T, Kato Y, Baba Y. Nasopharyngeal leiomyomatous hamartoma: case report. BMC Ear Nose Throat Disord 14: 5, 2014. doi: 10.1186/1472-6815-14-5 [Pub-Med]
29. Kobayashi R, Terakawa J, Kato Y, Azimi S, Inoue N, Ohmori Y, Hondo E. The contribution of leukemia inhibitory factor (LIF) for embryo implantation differs among strains of mice. Immunobiology 219(7): 512-21, 2014. doi: 10.1016/j.imbio.2014.03.011 [Pub-Med]
30. Hata R, Izukuri K, Kato Y, Sasaki S, Mukaida N, Maehata Y, Miyamoto C, Akasaka T, Yang X, Nagashima Y, Takeda K, Kiyono T, Taniguchi M. Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice. Sci Rep 5, 9083, 2015. doi:10.1038/srep09083 [Pub-Med]
31. Suzuki A, Maeda T, Baba Y, Shimamura K, Kato Y. Acidic extracellular pH promotes epithelial mesenchymal transition in Lewis lung carcinoma model. Cancer Cell Int, 2014, 14: 129. doi:10.1186/s12935-014-0129-1 [Pub-Med]
32. Baba Y, Fujii M, Maeda T, Suzuki A, Yuzawa S, Kato Y. Deguelin induced apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines. BioMed Res Int 657179, 2014. doi: 10.1155/2015/657179 [Pub-Med]
33. Baba Y, Kato Y. Hemangioma with phleboliths in the floor of the mouth presenting as a submental swelling: a case report. J Med Cases 2(1): 28-30, 2011. [Publisher site]
34. Baba Y, Kato Y, Ogawa K. Unusual computed tomography findings of radionecrosis after chemoradiation of stage IV hypopharyngeal cancer: a case report. J Med Case Rep 5(1): 25, 2011. [Pub-Med]
35. Baba Y, Kato Y, Ogawa K. Hyperplasia of lymphoid structures in the hypopharynx: a case report. J Med Case Rep 4: 388, 2010. [Pub-Med]
36. Nakazaki K, Kato Y, Taguchi T, Inayama Y, Ishiguro Y, Tsukuda M. Heterozygous mutation (G/G→G/A) at nt 2607 of the EGFR gene is closely associated with increases in EGFR copy number and mRNA half life, but impaired EGFR protein synthesis in squamous cell carcinomas of the head and neck - implication for gefitinib efficacy. Oncol Lett 1: 1017-1020, 2010. [Pub-Med]
37. Maehata Y, Ozawa S, Kobayashi K, Kato Y, Yoshino F, Miyamoto C, Izukuri K, Kubota E, Hata RI, Lee MC. Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells. Free Radical Res 44(8): 913-924, 2010. [Pub-Med]
38. Ozawa S, Ito S, Kato Y, Kubota E, Hata RI. Human p38delta MAP kinase mediates UV irradiation induced up-regulation of the gene expression of chemokine BRAK/CXCL14. Biochem Biophys Res Commun 396(4) 1060-1064, 2010. [Pub-Med]
39. Komori R, Ozawa S, Kato Y, Shinji H, Kimoto S, Hata RI. Functional characterization of proximal promoter of gene for human chemokine BRAK/CXCL14. Biomed Res 31(2): 123-131, 2010. [Pub-Med]
40. Sato K, Ozawa S, Izukuri K, Kato Y, Hata RI. Expression of tumor-suppressing chemokine BRAK/ CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro. Cell Biol Int 34: 513-522, 2010. [Pub-Med]
41. Baba Y, Kato Y, Ogawa K. Inostamycin prevents malignant phenotype of cancer: inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma. Cell Biol Int 34(2):171-175, 2010. [Pub-Med]
42. Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D₃ synthesis in leptin-deficient mice. J. Bone Miner. Res. 25(8): 1711-23, 2010. [Pub-Med]